Vertex Pharmaceuticals Incorporated

Published : July 05th, 2015

1:46 pm Vertex Pharma confirms FDA approval of its ORKAMBI to treat the underlying cause of cystic fibrosis in people ages 12 and older (shares remain halted)

( 0 vote, 0/5 ) Print article
  Article Comments Comment this article Rating Follow Company  
0
Send
0
comment

1:46 pm Vertex Pharma confirms FDA approval of its ORKAMBI to treat the underlying cause of cystic fibrosis in people ages 12 and older (shares remain halted)

5:30 am Prima Biomed receives positive Scientific Advice from the EMA on the development path for its lead product, IMP321 in metastatic breast cancer (PBMD) : After dialogue between Prima and the EMA, the Agency has now confirmed in writing its endorsement of the development program of IMP321 in metastatic breast cancer. The planned Phase IIb study, to be called AIPAC (Active Immunotherapy PAClitaxel) is considered well designed by the Agency. AIPAC is now expected to initiate in Europe during the 4th quarter of 2015. While the EMA never endorses any statement on the likelihood of future regulatory decisions, the Agency's communication has suggested that the achievement of certain clinical endpoints may lead to Marketing Authorization in the EU based on this one pivotal study.

  • After a smaller safety run-in phase that will extend into 2016 and will yield valuable safety, pharmacokinetic and pharmacodynamic data, AIPAC will proceed to recruit around 200 patients with HER-2 negative metastatic breast cancer, randomising them 1:1 to either standard-of-care paclitaxel plus placebo or paclitaxel plus IMP321. The trial will have Progression-Free Survival as its Primary Endpoint, with response rates according to the RECIST criteria and Overall Survival among the secondary endpoints. The study has been powered to show a four-month PFS advantage for the treatment group1. 
  • Allowing time for patient recruitment and follow-up, AIPAC's expected duration is around three years.

4:34 am Mazor Robotics receives 7 purchase orders for its Renaissance Systems in Q2 (MZOR) : Co announced that it received purchase orders for and delivered seven Renaissance systems and one system upgrade in the second quarter ended June 30, 2015.

  • Six of the systems were delivered to U.S. hospitals and one was delivered to Spain. 
  • The Company ended the quarter with 93 Renaissance systems installed globally, with 53 in the U.S., the Company's primary growth market, compared with 72 and 39 systems for the second ended June 30, 2014, respectively.

3:38 am Israel Chemical resumes production of polymeric flame retardant following end of labor strike (ICL) : Co announced that its ICL Industrial Products segment has resumed commercial production of its FR-122P polymeric flame retardant following the end of a labor strike at its 10,000 MT/year plant in Israel. ICL IP also produces FR-122P at a 2,400 MT/year plant in the Netherlands.

  • ICL IP also announced today that it is ceasing production and phasing out sales of its HBCD product, FR-1206, excluding sales based on existing commitments to customers, and in line with the phase out dates of REACH and POP legislation.

3:32 am Travelport Worldwide acquires privately held Mobile Travel Technologies; terms not disclosed (TVPT) : Travelport Worldwide has acquired Mobile Travel Technologies, a private company based in Dublin, Ireland.

  • MTT provides an industry-leading mobile travel platform and product set that allows airlines, hotels, corporate travel management companies and travel agencies to engage with their customers through sophisticated, tailored mobile services including apps, mobile web and intelligent mobile messaging. 

3:15 am On The Wires (:WIRES) :

  • NVIDIA (NVDA) announced updates to its GPU-accelerated deep learning software that will double deep learning training performance. The new software will empower data scientists and researchers to supercharge their deep learning projects and product development work by creating more accurate neural networks through faster model training and more sophisticated model design. 
  • KKR (KKR) together with Hines Italia Value Added Fund, a fund managed by Hines Italia SGR, and COIMA, announced the acquisition of five telecom assets leased to Telecom Italia (TI). The portfolio has a total area of 35,500 square metres. It consists of five separate sites, in Rome, Monza, Parma, San Remo and Pavia.

2:20 am On The Wires (:WIRES) :

  • Spok (SPOK) announced that it has partnered with Thailand-based medical distributor Xovic to enable healthcare organisations to improve efficiency and safety with better staff communications. Through this partnership, Xovic distributes Spok's clinical alerting and secure smartphone messaging solutions to hospitals in Thailand. 
  • Constellium N.V. (CSTM) announced that it has formed a partnership with STELIA Aerospace and CT INGENIERIE to engage in a research and development project called FAST, focused on topological optimization of aero structures and additive manufacturing, also known as 3D printing.

1:13 am Silver Wheaton receives CRA Proposal Letter; does not require the Company to pay any amount to the CRA at this time. (SLW) : Co announces that it has received a proposal letter dated July 6, 2015 from the Canada Revenue Agency in which the CRA is proposing to reassess Silver Wheaton under various rules contained in the Income Tax Act.

  • The Proposal outlines CRA's position that the transfer pricing provisions of the Income Tax Act relating to income earned by our foreign subsidiaries outside of Canada should apply such that the income of Silver Wheaton subject to tax in Canada should be increased for the 2005 to 2010 taxation years by approximately C$715 million ($567 million). The issuance of the Proposal does not require the Company to pay any amount to the CRA at this time. 
  • Management believes that the Company has filed its tax returns and paid applicable taxes in compliance with Canadian tax law. 
  • Silver Wheaton intends to vigorously defend its tax filing positions and is now in the process of preparing its response to the Proposal. 

1:08 am On The Wires (:WIRES) :

  • Banc of California, N.A., a wholly owned subsidiary of Banc of California (BANC), and Americas United Bank announced a definitive agreement for Americas United Bank, a minority-owned financial institution, to purchase two branch locations from Banc of California, N.A. The branches are located in Commerce and Santa Fe Springs, California. 
  • Woodside Energy and OneSubsea, a Cameron (CAM) and Schlumberger (SLB) company, jointly announce that OneSubsea has been awarded a front-end engineering and design contract for the proposed Woodside-operated Browse FLNG Development offshore northwest Australia.

12:58 am CenterPoint will pay additional interest on its 2.0% Zero-Premium Exchangeable Subordinated Notes due 2029 (CNP) : Additional Interest of $1.4520600 per ZENS note will be paid on July 24, 2015 to holders of record as of the close of business on July 10, 2015, and Additional Interest of $0.8206900 per ZENS note will be paid on July 28, 2015 to holders of record as of the close of business on July 14, 2015.

12:49 am Euronet acquires XE to enhance its Money Transfer Business (EEFT) : Euronet Worldwide announced it has acquired XE, a digital foreign exchange information co.

  • Euronet will use approximately $60 million from its revolving credit agreement together with approximately 640,000 Euronet shares and an undisclosed amount of cash to complete the acquisition. 
  • XE's foreign currency payments are currently processed through a vendor, and Euronet expects XE's annual revenue of approximately $10 million to improve to ~$22 million once the payments processing is converted to Euronet's platform at HiFX.

12:45 am BDCA Venture encourages stockholders to vote on the WHITE proxy card for all co's director nominees (BDCV) :  

12:41 am SAExploration Holdings completes first major deep water ocean-bottom marine seismic project a week ahead of schedule (SAEX) : Co announced that it has successfully completed its first major deep water ocean-bottom marine seismic project. The project, which was located in Southeast Asia and utilized an advanced remotely operated vehicle deployment method at water depths reaching 1,100 meters, was completed over a week ahead of schedule, leading to meaningful cost savings for the customer. Superior planning and project execution led to enhanced performance despite the challenging and complex operating conditions.

Read the rest of the article at finance.yahoo.com
Data and Statistics for these countries : Australia | Canada | Ireland | Israel | Netherlands | Spain | Thailand | All
Gold and Silver Prices for these countries : Australia | Canada | Ireland | Israel | Netherlands | Spain | Thailand | All

CODE :
Follow and Invest
Add to watch list Add to your portfolio Add or edit a note
Add Alert Add to Watchlists Add to Portfolio Add Note
ProfileMarket
Indicators
VALUE :
Projects & res.
Press
releases
Annual
report
RISK :
Asset profile
Contact Cpy

Vertex Pharma is based in United states of america.

Vertex Pharma is listed in United States of America. Its market capitalisation is US$ 100.2 billions as of today (€ 93.4 billions).

Its stock quote reached its lowest recent point on March 12, 2004 at US$ 10.00, and its highest recent level on May 01, 2024 at US$ 402.14.

Vertex Pharma has 249 070 000 shares outstanding.

Your feedback is appreciated, please leave a comment or rate this article.
Rate : Average note :0 (0 vote) View Top rated
 
Corporate news of
1/27/2016Will Vertex Pharmaceuticals’ Valuation Multiple Improve?
1/26/2016Health Canada Approves PrORKAMBI® (lumacaftor/ivacaftor) - t...
1/26/20165:23 pm Vertex Pharma: Health Canada approves PrORKAMBI
1/26/2016Orkambi: Recent Addition to the Vertex Portfolio
1/26/2016Vertex draws upside bet before earnings
1/25/2016Will Higher Expenses Hurt Vertex's (VRTX) 4Q Earnings?
1/25/2016What Are Wall Street’s Estimates for Vertex Pharmaceuticals?
1/25/2016Vertex Pharmaceuticals: What Are Analysts’ Estimates?
1/20/2016Despite Market and Sector Risks, Why Credit Suisse Now Loves...
1/18/2016Nivalis' N91115 Gets Orphan Drug Status for Cystic Fibrosis
1/15/20164 Biotech Stocks Looking Good this Earnings Season
1/15/2016Vertex Pharmaceuticals (VRTX) Jumps: Stock Moves Up 5.8%
1/5/2016Vertex Announces Upcoming Presentation at the J.P. Morgan He...
12/30/2015Vertex Up 3.2% as Healthcare Sector Continued to Lure Invest...
12/23/2015Vertex Drives IBB’s Large-Caps after Losing for Two Days
12/1/2015Do Hedge Funds Love Intercontinental Exchange Inc (ICE)?
11/27/2015The Zacks Analyst Blog Highlights: BioMarin, Amgen, Vertex, ...
11/23/2015Vertex to Present at the Piper Jaffray Healthcare Conference...
11/23/2015Vertex Appoints Michael J. Parini as Executive Vice Presiden...
11/20/2015Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaft...
11/19/2015Vertex Rises on Two EU Approvals for Drug, Leads XLV’s Large...
11/4/2015Vertex to Present at the Credit Suisse Healthcare Conference...
11/2/2015Health-Care Subpoenas: Should We Start to Worry?
11/2/2015Here’s Why These Four Stocks Are Trending Today
11/2/2015IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Inves...
10/31/2015Vertex Pharma receives subpoena from Department of Justice
10/30/2015Law Offices of Howard G. Smith Commences Investigation on Be...
10/30/2015Vertex, Mylan, CVS subpoenaed by federal agencies
10/30/2015SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On...
10/30/2015Nivalis (NVLS): A Surprise in Store this Earnings Season?
10/29/2015Vertex (VRTX) Posts Narrower Q3 Loss, Ups Kalydeco View
10/29/2015Edited Transcript of VRTX earnings conference call or presen...
10/28/2015Vertex Reports Third Quarter 2015 Financial Results
10/28/2015Vertex reports 3Q loss
10/28/20154:07 pm Vertex Pharma beats by $0.14, beats on revs; raises ...
10/27/2015Will Orkambi Help Vertex (VRTX) Post a Lower Loss in Q3?
10/26/2015Vertex and CRISPR Therapeutics Establish Collaboration to Us...
10/26/20158:03 am Vertex Pharma and CRISPR Therapeutics enter strategi...
10/20/2015Oppenheimer Incrementally More Bullish on Gilead, Remains Ca...
10/12/2015Why Energy Stocks Outperformed the Broad Market on October 6
10/9/2015Vertex to Announce Third Quarter 2015 Financial Results on O...
10/8/2015SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Invest...
10/8/2015Vertex's Kalydeco Gets Priority Review for Expanded Use
10/8/2015Vertex Announces Significant Progress in Its Development Eff...
10/7/2015Supplemental New Drug Application for Use of KALYDECO® (ivac...
10/7/2015Supplemental New Drug Application for Use of KALYDECO® (ivac...
10/7/2015Supplemental New Drug Application for Use of KALYDECO® (ivac...
10/7/2015BioMarin Pharmaceutical Takes a Nosedive Last Week
10/1/2015The Zacks Analyst Blog Highlights: Regeneron, Vertex, Gilead...
9/29/2015Regeneron and Mylan End Up in Green for the Week
9/28/2015Why Argus Thinks Now Is the Time to Buy Vertex
9/25/2015IBB Remained Flat Last Week
9/25/2015Vertex Receives CHMP Positive Opinions for ORKAMBI™ (lumacaf...
9/23/2015XBI’s Biotechnology Stocks Rose Week of September 11
9/22/20155 Biotech Stocks Hit Hard by Hillary Clinton's Tweet
9/22/2015Vertex Outperforms XLV on a Year-to-Date Basis
9/21/2015Biotech stocks fall on Clinton vow to fight 'price gouging'
9/18/2015SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Invest...
9/16/2015XLV and XBI Outperform Benchmark Indexes from August 25–31
9/14/2015Amgen And Biogen Lead Short Interest Surge In Biotechs
9/14/2015Vertex Helps Biotechnology Sector Outperform
9/14/2015How Will Vertex Solve Its Falling Revenue Woes?
9/14/2015Vertex Pharma's Orkambi Gives It Huge Potential, Says Barcla...
9/11/2015Vertex and Biogen Outperformd XLV and SPY
9/8/2015Vertex to Present at the Morgan Stanley Healthcare Conferenc...
8/22/2015How Does Vertex Compare to Its Peers?
8/21/2015Vertex Stock Rises after 2Q15 Results Announcement
8/21/2015Will Orkambi Be a Game Changer for Vertex?
8/19/2015Vertex Awards Two Boston Public High School Students the Ver...
8/11/2015What Drove Vertex’s Revenue in 2Q15?
8/11/2015Vertex Reports 2Q15 Revenues of $166.1 Million
8/11/2015What Led Large-Cap Stocks to Outperform Mid and Small Caps?
8/10/2015Key for Investors: How Are Biotech Stocks Trending?
8/10/2015Biotech Stocks Rise Due to a Stable Market: July 31 Week
8/6/2015The Zacks Analyst Blog Highlights: Amgen, Vertex, Regeneron,...
8/4/20153 Potential Huge Takeover Targets in Biotech
7/31/2015Advanced Estimate: US 2Q Gross Domestic Product Expanded by ...
7/30/2015Vertex Posts Wider Y/Y Loss but Raises Kalydeco Outlook - An...
7/30/2015Large-Cap Healthcare Stocks Outperform Small Caps
7/30/2015Edited Transcript of VRTX earnings conference call or presen...
7/29/2015Vertex Reports Second Quarter 2015 Financial Results
7/29/2015Vertex reports 2Q loss
7/28/2015Will Vertex (VRTX) Surprise with a Lower Loss in Q2? - Analy...
7/28/2015CRBP: Warrant Exercise To Provide Sufficient Cash Through 20...
7/24/2015What to Watch in the Week Ahead and on Monday, July 27
7/21/2015How High? The Backlash Over Rising Prescription Drug Prices ...
7/14/2015Vertex to Announce Second Quarter 2015 Financial Results on ...
7/6/2015Vertex Pharma Is 'Hyped,' H.C. Wainwright Sees 35% Downside
7/5/2015Evercore ISI Analyst Gives Highlights From Vertex's Orkambi ...
7/5/20151:46 pm Vertex Pharma confirms FDA approval of its ORKAMBI t...
7/2/2015Business Highlights
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015FDA clears drug for leading form of cystic fibrosis
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015Vertex Pharma's lung disorder therapy wins FDA nod
7/2/2015Vertex Shares Leap On FDA Approval For Cystic Fibrosis Combo...
7/2/2015FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Med...
6/18/2015Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Direc...
6/12/2015Edited Transcript of VRTX presentation 11-Jun-15 4:20pm GMT
5/8/2015FDA questions benefit of cystic fibrosis drug from Vertex
4/23/2015Why Vertex Pharmaceuticals (VRTX) Stock Might be a Great Pic...
4/21/2015Gilead's Stock Spikes on Possibility of Vertex Deal
4/21/2015Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC C...
4/21/2015Bernstein: It's Time For Gilead To Pull The Trigger On This ...
4/17/2015Biotech Investors Shouldn't Miss These Stocks This Earnings ...
4/15/2015Will a New Vertex Drug for Cystic Fibrosis Become a Budget B...
4/9/2015Vertex to Announce First Quarter 2015 Financial Results on A...
4/8/2015Stock Market News for April 08, 2015 - Market News
3/26/2015The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex,...
3/26/2015One analyst is convinced the biotech stock plunge is 'misgui...
3/24/2015Vertex Falls on Disappointing Kalydeco+VX-661 Combo Data - A...
3/24/2015Vertex Treatment May Have High Risk of Failure, Analyst Sugg...
3/24/2015Stock Market News for March 24, 2015 - Market News
3/23/2015Deutsche Bank: Vertex Pharma's Disappointing VX-661 Trial Re...
3/23/2015Vertex Falls Below Buy Point On Cystic-Fibrosis Drug Data
3/23/2015Pfizer and ImmunoGen are big market movers
3/23/2015ICYMI: Pharmaceutical Stocks Are Moving Big On Monday
Comments closed
 
Latest comment posted for this article
Be the first to comment
Add your comment
NASDAQ (VRTX)
402.14+2.38%
US$ 402.14
05/01 17:00 9.33
2.38%
Prev close Open
392.81 392.81
Low High
392.47 406.90
Year l/h YTD var.
392.81 -  446.08 -2.13%
52 week l/h 52 week var.
323.57 -  446.08 16.22%
Volume 1 month var.
1,163,388 -1.78%
Produces
Develops
Explores for
 
 
 
Analyse
Interactive chart Add to compare
Interactive
chart
Print Compare Export
You must be logged in to use the porfolio and watchlists (free)
Top Newsreleases
MOST READ
Annual variation
DateVariationHighLow
202414.24%
202321.89%367.00282.41
202230.17%324.75219.10
2021-6.14%238.26176.36
20206.96%306.08197.47
 
5 years chart
 
3 months chart
 
3 months volume chart
 
 
Mining Company News
Plymouth Minerals LTDPLH.AX
Plymouth Minerals Intersects Further High Grade Potash in Drilling at Banio Potash Project - Plannin
AU$ 0.12-8.00%Trend Power :
Santos(Ngas-Oil)STO.AX
announces expected non-cash impairment
AU$ 7.44-1.26%Trend Power :
OceanaGold(Au)OGC.AX
RELEASES NEW TECHNICAL REPORT FOR THE HAILE GOLD MINE
AU$ 2.20+0.00%Trend Power :
Western Areas NL(Au-Ni-Pl)WSA.AX
Advance Notice - Full Year Results Conference Call
AU$ 3.86+0.00%Trend Power :
Canadian Zinc(Ag-Au-Cu)CZN.TO
Reports Financial Results for Q2 and Provides Project Updates
CA$ 0.12+4.55%Trend Power :
Stornoway Diamond(Gems-Au-Ur)SWY.TO
Second Quarter Results
CA$ 0.02+100.00%Trend Power :
McEwen Mining(Cu-Le-Zn)MUX
TO ACQUIRE BLACK FOX FROM PRIMERO=C2=A0
US$ 11.55+0.79%Trend Power :
Rentech(Coal-Ngas)RTK
Rentech Announces Results for Second Quarter 2017
US$ 0.20-12.28%Trend Power :
KEFIKEFI.L
Reduced Funding Requirement
GBX 0.53-1.12%Trend Power :
Lupaka Gold Corp.LPK.V
Lupaka Gold Receives First Tranche Under Amended Invicta Financing Agreement
CA$ 0.06+0.00%Trend Power :
Imperial(Ag-Au-Cu)III.TO
Closes Bridge Loan Financing
CA$ 2.63-0.75%Trend Power :
Guyana Goldfields(Cu-Zn-Pa)GUY.TO
Reports Second Quarter 2017 Results and Maintains Production Guidance
CA$ 1.84+0.00%Trend Power :
Lundin Mining(Ag-Au-Cu)LUN.TO
d Share Capital and Voting Rights for Lundin Mining
CA$ 15.35-2.35%Trend Power :
Canarc Res.(Au)CCM.TO
Canarc Reports High Grade Gold in Surface Rock Samples at Fondaway Canyon, Nevada
CA$ 0.26+4.08%Trend Power :
Havilah(Cu-Le-Zn)HAV.AX
Q A April 2017 Quarterly Report
AU$ 0.22-6.52%Trend Power :
Uranium Res.(Ur)URRE
Commences Lithium Exploration Drilling at the Columbus Basin Project
US$ 6.80-2.86%Trend Power :
Platinum Group Metals(Au-Cu-Gems)PTM.TO
Platinum Group Metals Ltd. Operational and Strategic Process ...
CA$ 1.83+5.17%Trend Power :
Devon Energy(Ngas-Oil)DVN
Announces $340 Million of Non-Core Asset Sales
US$ 50.42-1.48%Trend Power :
Precision Drilling(Oil)PD-UN.TO
Announces 2017Second Quarter Financial Results
CA$ 8.66-0.35%Trend Power :
Terramin(Ag-Au-Cu)TZN.AX
2nd Quarter Report
AU$ 0.04+0.00%Trend Power :